VIDEO ACCESS:

• MAYO STAFF: Access this pre-recorded session on the Video Exchange website.

RELEASE: February 17, 2016
EXPIRATION: December 31, 2017 (Credit is not available after this expiration date)

1st PRESENTER: Shirshendu Sinha, MBBS
TITLE:  Universal Precautions to Reduce Stimulant Misuse in Treating Adult ADHD
Shirshendu Sinha M.B.B.S. is a board certified general adult psychiatrist and clinical fellow in Addictive Disorders at the Mayo Clinic in Rochester, MN. He graduated from North Bengal Medical College and Hospital, West Bengal, India. He then traveled across the continents and joined the dysproteinemia group as a post-doctoral research fellow at the Mayo Clinic, Rochester, MN. He was impressed by the astounding success of novel therapies that improve outcomes and quality of life among cancer patients. At the same time, he became aware of, and sympathized with, the frustrations and mental distress of patients with suffering from cancer and this distilled a keen interest in the field of psychiatry. He completed adult psychiatry residency training at University of Connecticut School of Medicine, Farmington, CT where he also served as Education Chief Resident. His research and scholarly pursuits in over various research projects have been highlighted in no fewer than 14 peer-reviewed papers, the majority with Dr. Sinha as primary author.  Additionally he authored over 30 abstracts and presentations. He has received awards from Janssen Academic Research Mentorship Program, American Society of Clinical Psychopharmacology, Neuroscience Education Institute and American Academy of Addiction Psychiatry. Dr. Sinha has a strong interest in addiction, neuroscience and psychopharmacology. He is currently serving as the section editor for Neurology and Neuroscience, in an upcoming board review book from Oxford University Press. He is one of the editors for Indo-American Psychiatric Association Newsletter. He is also a member of the American Academy of Addiction Psychiatry‘s Youth and Adolescent Committee.

LEARNING OBJECTIVES

1. Recognize the signs and symptoms of adult Attention Deficit Hyperactive Disorder
2. Demonstrate knowledge on practice parameter for the use of stimulant medications in this population

2nd PRESENTER: Chad Puffer, DO
TITLE: Towards a Better Understanding of Mental Health Needs in the Rochester Community
Dr. Puffer completed undergraduate training in Biology at Luther College, where he received a Bachelor of Arts degree in 2006.  He then attended Kansas City University of Medicine and Biosciences, and received the degree of Doctor of Osteopathy in 2011.  He is currently a Psychiatry resident in his 5^th year of training and will graduate in June 2016 after completing the General Psychiatry Residency as well as a fellowship in Child and Adolescent Psychiatry.  He has accepted a position with Prairie Care and will work as a Child Psychiatrist in their Intensive Outpatient Program here in Rochester.   Dr. Puffer’s interests include the treatment of pediatric mood and anxiety disorders.  He has presented research findings at the National Network of Depression Centers annual conference, as well as the American Psychiatric Association annual meeting.

LEARNING OBJECTIVES

1. Review the history of electroconvulsive therapy for adult and pediatric populations
2. Recognize the indications for treatment of pediatric mental illness with electroconvulsive therapy
3. Describe the expected treatment course, side effects, and outcomes of electroconvulsive therapy in the pediatric population

ACCREDITATION
Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Mayo Clinic College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensuracte with the extent of their participation in the activity.

INSTRUCTIONS:

• Select the Take Course button below.
• Participate in the quiz.  Participants must pass by a minimum of 80%, 1 re-take is allowed.  Quizzes will have between 2-5 questions.
• Complete the evaluation.

TRANSCRIPT:
This credit will appear on your Transcript for permanent record.  To access your transcript, visit My Account, My Activities, Transcript

DISCLOSURE SUMMARY:
As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Dr. Sinha - Grant/research support with Janssen (Johnson & Johnson) Academic Research Mentorship Program and travel/membership waiver with American Society of Clinical Psychopharmacology, Neuroscience Education Institute.

No relevant financial relationship(s) with industry:
Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, M.D., Patricia Maus, M.D., Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D.

Presenters: Chad Puffer, DO

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
Dr. Sinha - Product(s)/Device(s): Bupropion , Clonidine , Guanfacine , Desipramine 
Chad Puffer, DO - Manufacturer(s)/Provider(s): ECT devices are class 3 devices as defined by the FDA, and legal regulation varies from state to state. 

QUESTIONS?
MAYO STAFF: Contact rstpsychgr@mayo.edu.